CMRX Stock Overview
About the company
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Snowflake Analysis
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Chimerix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.28 |
| 52 Week High | US$5.39 |
| 52 Week Low | US$1.27 |
| Beta | 1.18 |
| 1 Month Change | -22.42% |
| 3 Month Change | -34.02% |
| 1 Year Change | -74.90% |
| 3 Year Change | -1.54% |
| 5 Year Change | -76.07% |
| Change since IPO | -93.19% |
Recent News & Updates
Recent updates
Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation
Aug 23Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation
Jul 20
Chimerix: Down But Not Out
Jun 06Chimerix: Searching For Clarity
Jan 05Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?
Dec 24Is Chimerix (NASDAQ:CMRX) A Risky Investment?
Sep 16Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?
Jun 08Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox
Jun 04Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?
May 13Chimerix Investor Presentation - Slideshow
May 08Chimerix expands oncology program with acquisition of Oncoceutics, shares up 10%
Jan 08Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?
Jan 01
Chimerix rises 9.1% premarket after FDA accepts NDA for smallpox countermeasure
Dec 07Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans
Dec 05Chimerix, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Chimerix EPS misses by $0.01, beats on revenue
Nov 05Shareholder Returns
| CMRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.9% | 2.1% | 0.9% |
| 1Y | -74.9% | -3.3% | -13.7% |
Return vs Industry: CMRX underperformed the US Biotechs industry which returned -3.3% over the past year.
Return vs Market: CMRX underperformed the US Market which returned -13.7% over the past year.
Price Volatility
| CMRX volatility | |
|---|---|
| CMRX Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CMRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CMRX's weekly volatility has decreased from 15% to 7% over the past year.
Chimerix, Inc. Fundamentals Summary
| CMRX fundamental statistics | |
|---|---|
| Market Cap | US$112.99m |
| Earnings (TTM) | US$172.17m |
| Revenue (TTM) | US$33.82m |
0.7x
P/E Ratio3.3x
P/S RatioIs CMRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMRX income statement (TTM) | |
|---|---|
| Revenue | US$33.82m |
| Cost of Revenue | US$70.31m |
| Gross Profit | -US$36.49m |
| Other Expenses | -US$208.65m |
| Earnings | US$172.17m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.95 |
| Gross Margin | -107.87% |
| Net Profit Margin | 509.01% |
| Debt/Equity Ratio | 0% |
How did CMRX perform over the long term?
See historical performance and comparison